Latest News
Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pembrolizumab in first-line treatment of recurrent o...
Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026
26 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Sunday the presentation of results from the randomised, controlled, double-blind, multicentre, registrational Phase III HARMONi-GI1 trial (AK112-309).The study eva...
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
26 October 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (Kelun-Biotech) (HKG:6990) announced on Sunday the presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, of ...
Zhejiang Wenda Pharma reports positive NHWD-870 HCl oral BET inhibitor Phase II trial results at 2026 ESMO Annual Meeting
26 October 2026 - China-based Zhejiang Wenda Pharmaceutical Technology Co Ltd announced on Sunday the publication of its phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC) at the...
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
26 October 2026 - Commercial-stage biopharmaceutical company Bio-Thera Solutions Ltd (SHA:688177) announced on Saturday the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an ant...